Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).
NCT00741325 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 178
Last updated 2014-02-11
Summary
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3101 protocol (NCT00103610).
Conditions
- Non-Hodgkin's Lymphoma
- Autologous Transplantation
Interventions
- DRUG
-
granulocyte colony-stimulating factor (G-CSF)
- DRUG
-
plerixafor
- DRUG
Sponsors & Collaborators
-
Genzyme, a Sanofi Company
lead INDUSTRY
Principal Investigators
-
Medical Monitor · Genzyme, a Sanofi Company
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-06-30
- Primary Completion
- 2011-11-30
- Completion
- 2011-11-30
More Related Trials
-
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
NCT00396201 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
NCT00838357 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
NCT01164475 ·Status: COMPLETED ·Phase: PHASE4
-
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00052442 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
NCT01947140 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
NCT06561425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
NCT00720603 ·Status: NO_LONGER_AVAILABLE
-
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02570542 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01097057 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
NCT01431209 ·Status: COMPLETED ·Phase: PHASE2
-
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
NCT01408043 ·Status: TERMINATED ·Phase: NA
-
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03075553 ·Status: TERMINATED ·Phase: PHASE2
-
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
NCT03355768 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT05934513 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
NCT02464228 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06072131 ·Status: RECRUITING ·Phase: PHASE3
-
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00080847 ·Status: TERMINATED ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
NCT05441761 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06671717 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
NCT00481871 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Imexon for Relapsed Follicular and Aggressive Lymphomas
NCT01314014 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas
NCT01538641 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
NCT02495415 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
NCT00055640 ·Status: COMPLETED ·Phase: PHASE2